0000925421-20-000244.txt : 20200609
0000925421-20-000244.hdr.sgml : 20200609
20200609200201
ACCESSION NUMBER: 0000925421-20-000244
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200605
FILED AS OF DATE: 20200609
DATE AS OF CHANGE: 20200609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NOVARTIS AG
CENTRAL INDEX KEY: 0001114448
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39114
FILM NUMBER: 20953246
BUSINESS ADDRESS:
STREET 1: LICHTSTRASSE 35
CITY: BASEL
STATE: V8
ZIP: CH 4056
BUSINESS PHONE: 01141613241111
MAIL ADDRESS:
STREET 1: LICHTSTRASSE 35
CITY: BASEL
STATE: V8
ZIP: CH 4056
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novartis Bioventures Ltd
CENTRAL INDEX KEY: 0001297709
STATE OF INCORPORATION: D0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39114
FILM NUMBER: 20953247
BUSINESS ADDRESS:
STREET 1: C/O NOVARTIS INTERNATIONAL AG
STREET 2: WSJ-200.220
CITY: CH-4002 BASEL
STATE: V8
ZIP: 0000000000
BUSINESS PHONE: 41-61-324-6210
MAIL ADDRESS:
STREET 1: C/O NOVARTIS INTERNATIONAL AG
STREET 2: WSJ-200.220
CITY: CH-4002 BASEL
STATE: V8
ZIP: 0000000000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Galera Therapeutics, Inc.
CENTRAL INDEX KEY: 0001563577
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 461454898
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 WEST LIBERTY BLVD #100
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 610-725-1500
MAIL ADDRESS:
STREET 1: 2 WEST LIBERTY BLVD #100
CITY: MALVERN
STATE: PA
ZIP: 19355
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2020-06-05
0001563577
Galera Therapeutics, Inc.
GRTX
0001297709
Novartis Bioventures Ltd
FORUM 1 - 1.32, LICHTSTRASSE 35, CH-4056
BASEL
V8
CH-4056
SWITZERLAND
0
0
1
0
0001114448
NOVARTIS AG
LICHTSTRASSE 35, CH-4056
BASEL
V8
CH-4056
SWITZERLAND
0
0
1
0
Common Stock
2020-06-05
4
S
0
8652
9.66
D
3519450
D
Common Stock
2020-06-08
4
S
0
5659
9.66
D
3513791
D
Common Stock
2020-06-09
4
S
0
7000
9.38
D
3506791
D
Reflects sales of common stock executed in multiple transactions at prices ranging from $9.35 to $9.89. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.
Reflects sales of common stock executed in multiple transactions at prices ranging from $9.50 to $9.83. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of common stock executed in multiple transactions at prices ranging from $9.30 to $9.56. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
/s/ Bartosz Dzikowski, Secretary of the Board of Novartis Bioventures Ltd
2020-06-09
/s/ Beat Steffen, Authorized Signatory on behalf of Novartis Bioventures Ltd
2020-06-09
/s/ Bartosz Dzikowski, Authorized Signatory on behalf of Novartis AG
2020-06-09
/s/ Beat Steffen, Authorized Signatory on behalf of Novartis AG
2020-06-09